國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

The Patentability of Medical Product...

Stuhldreier, Marc Andre.

The Patentability of Medical Products: Identifying Responsibilities of Pharmaceutical Corporations Towards the Right to Health.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	The Patentability of Medical Products: Identifying Responsibilities of Pharmaceutical Corporations Towards the Right to Health.
作者:	Stuhldreier, Marc Andre.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, 2019
面頁冊數:	353 p.
附註:	Source: Dissertations Abstracts International, Volume: 82-01, Section: B.
附註:	Advisor: Brewer, Mark;Farran, Sue.
Contained By:	Dissertations Abstracts International82-01B.
標題:	Patent law.
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27991999
ISBN:	9798643189558

The Patentability of Medical Products: Identifying Responsibilities of Pharmaceutical Corporations Towards the Right to Health.
Stuhldreier, Marc Andre.

The Patentability of Medical Products: Identifying Responsibilities of Pharmaceutical Corporations Towards the Right to Health. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 353 p.

Source: Dissertations Abstracts International, Volume: 82-01, Section: B.

Thesis (Ph.D.)--University of Northumbria at Newcastle (United Kingdom), 2019.

This item must not be sold to any third party vendors.

Each year, billions of people lack adequate access to urgently required medicines, leading to unnecessary suffering and the loss of millions of lives from preventable conditions. One of the main causes of this situation is that individuals living in extreme poverty cannot afford the prices of essential medicines, and the health-care systems of poverty-ridden developing countries are incapable of providing the required medications to their population. Exclusive patent rights contribute to the severity of this situation by providing the legal frameworks which enable pharmaceutical corporations to charge exorbitant prices for their patented drugs. Therefore, the global introduction of the patentability of pharmaceutical products under the WTO's TRIPS Agreement constitutes one of the main threats to the realisation of the Right to Health in developing countries.This thesis addresses conflicting provisions of the human right to health and patent rights under international trade agreements, scrutinising whether there exists a legal hierarchy between human rights and trade law, or whether there are moral reasons suggesting that one should be superior to the other. Identifying that currently a legal hierarchy cannot be established, but that moral reasons suggest the superior importance of human rights, this thesis addresses the justifiability of the current international patent regime.The main findings of this thesis suggest that the current international patent regime cannot be regarded as justified; either from a human rights perspective, or within itself. It is therefore submitted, that the international patent system urgently requires to be changed with respect to its regulations on the patentability of medical products. This thesis then proposes that the international patent regime offers the distinct opportunity of implementing direct responsibilities of pharmaceutical patent holders as requirements for patentability within international trade law itself, for example by an amendment of the TRIPS Agreement. In presenting these possibilities, this thesis contributes a further dimension to ongoing debates about how the human rights responsibilities of the private business sector can be identified and effectively enforced.

ISBN: 9798643189558Subjects--Topical Terms:

766021
Patent law.
Subjects--Index Terms:

Pharmaceutical products

The Patentability of Medical Products: Identifying Responsibilities of Pharmaceutical Corporations Towards the Right to Health.
LDR:03480nmm a2200361 4500 001 594569
005 20210521101656.5
008 210917s2019 ||||||||||||||||| ||eng d
020 $a 9798643189558
035 $a (MiAaPQ)AAI27991999
035 $a (MiAaPQ)Northumbria_42020
035 $a AAI27991999
040 $a MiAaPQ $c MiAaPQ
100 1 $a Stuhldreier, Marc Andre. $3 886583
245 1 4 $a The Patentability of Medical Products: Identifying Responsibilities of Pharmaceutical Corporations Towards the Right to Health.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 353 p.
500 $a Source: Dissertations Abstracts International, Volume: 82-01, Section: B.
500 $a Advisor: Brewer, Mark;Farran, Sue.
502 $a Thesis (Ph.D.)--University of Northumbria at Newcastle (United Kingdom), 2019.
506 $a This item must not be sold to any third party vendors.
520 $a Each year, billions of people lack adequate access to urgently required medicines, leading to unnecessary suffering and the loss of millions of lives from preventable conditions. One of the main causes of this situation is that individuals living in extreme poverty cannot afford the prices of essential medicines, and the health-care systems of poverty-ridden developing countries are incapable of providing the required medications to their population. Exclusive patent rights contribute to the severity of this situation by providing the legal frameworks which enable pharmaceutical corporations to charge exorbitant prices for their patented drugs. Therefore, the global introduction of the patentability of pharmaceutical products under the WTO's TRIPS Agreement constitutes one of the main threats to the realisation of the Right to Health in developing countries.This thesis addresses conflicting provisions of the human right to health and patent rights under international trade agreements, scrutinising whether there exists a legal hierarchy between human rights and trade law, or whether there are moral reasons suggesting that one should be superior to the other. Identifying that currently a legal hierarchy cannot be established, but that moral reasons suggest the superior importance of human rights, this thesis addresses the justifiability of the current international patent regime.The main findings of this thesis suggest that the current international patent regime cannot be regarded as justified; either from a human rights perspective, or within itself. It is therefore submitted, that the international patent system urgently requires to be changed with respect to its regulations on the patentability of medical products. This thesis then proposes that the international patent regime offers the distinct opportunity of implementing direct responsibilities of pharmaceutical patent holders as requirements for patentability within international trade law itself, for example by an amendment of the TRIPS Agreement. In presenting these possibilities, this thesis contributes a further dimension to ongoing debates about how the human rights responsibilities of the private business sector can be identified and effectively enforced.
590 $a School code: 5060.
650 4 $a Patent law. $3 766021
650 4 $a Pharmaceutical sciences. $3 708611
650 4 $a Intellectual property. $3 198094
650 4 $a International law. $3 174617
653 $a Pharmaceutical products
653 $a Patent rights
690 $a 0513
690 $a 0616
690 $a 0572
690 $a 0562
710 2 $a University of Northumbria at Newcastle (United Kingdom). $3 886582
773 0 $t Dissertations Abstracts International $g 82-01B.
790 $a 5060
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27991999